COVID-19 in Iran: clinical presentations and outcomes in three different surges of COVID-19 infection.
ARDS
COVID-19
Comorbidities
Mortality
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
26 07 2022
26 07 2022
Historique:
received:
23
08
2021
accepted:
30
06
2022
entrez:
26
7
2022
pubmed:
27
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
A few studies compared the characteristics and outcomes of COVID-19 patients during the first and second surges of the disease. We aimed to describe the clinical features and outcomes of COVID-19 patients across the first, second, and third surges of the disease in Tehran, Iran. We conducted a retrospective cohort study of patients with COVID-19 admitted to Sina hospital in Tehran, Iran, during three surges of COVID-19 from February 16 to October 28, 2020. Surge 1 patients were younger with more prevalence of hypertension. They also presented with significantly higher oxygen saturation, systolic blood pressure, and respiratory rate on admission. Patients had higher levels of neutrophil to lymphocyte ratio, Urea, CRP, and ESR, in surge 2. The incidence of dyspnea, chest pain, and neurological manifestations followed a significant increasing trend from surge 1 to surge 3. There was no difference in severity and in-hospital mortality between the surges. However, the length of hospital stays and acute cardiac injury (ACI) was less in surge 1 and acute respiratory distress syndrome (ARDS) in surge 2 than in other surges. Patients did not significantly differ in disease severity, ICU admission, and mortality between surges; however, length of hospital stay and ACI increased during surges, and the number of patients developing ARDS was significantly less in surge 2 compared to other peaks.
Sections du résumé
BACKGROUND
A few studies compared the characteristics and outcomes of COVID-19 patients during the first and second surges of the disease. We aimed to describe the clinical features and outcomes of COVID-19 patients across the first, second, and third surges of the disease in Tehran, Iran.
METHOD
We conducted a retrospective cohort study of patients with COVID-19 admitted to Sina hospital in Tehran, Iran, during three surges of COVID-19 from February 16 to October 28, 2020.
RESULT
Surge 1 patients were younger with more prevalence of hypertension. They also presented with significantly higher oxygen saturation, systolic blood pressure, and respiratory rate on admission. Patients had higher levels of neutrophil to lymphocyte ratio, Urea, CRP, and ESR, in surge 2. The incidence of dyspnea, chest pain, and neurological manifestations followed a significant increasing trend from surge 1 to surge 3. There was no difference in severity and in-hospital mortality between the surges. However, the length of hospital stays and acute cardiac injury (ACI) was less in surge 1 and acute respiratory distress syndrome (ARDS) in surge 2 than in other surges.
CONCLUSION
Patients did not significantly differ in disease severity, ICU admission, and mortality between surges; however, length of hospital stay and ACI increased during surges, and the number of patients developing ARDS was significantly less in surge 2 compared to other peaks.
Identifiants
pubmed: 35883172
doi: 10.1186/s12985-022-01846-7
pii: 10.1186/s12985-022-01846-7
pmc: PMC9321282
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2012;7(7):e40515
pubmed: 22808179
JAMA. 2020 Sep 8;324(10):998-1000
pubmed: 32789492
PLoS One. 2022 May 17;17(5):e0265489
pubmed: 35580114
BMC Infect Dis. 2022 May 3;22(1):423
pubmed: 35505306
Intern Emerg Med. 2022 Apr;17(3):675-684
pubmed: 34637079
Sci Rep. 2021 May 27;11(1):11134
pubmed: 34045530
Lancet Diabetes Endocrinol. 2020 Jul;8(7):562-564
pubmed: 32437642
Crit Care Explor. 2021 Feb 22;3(2):e0346
pubmed: 33634266
Am J Hypertens. 2020 Dec 31;33(12):1102-1111
pubmed: 32920644
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Int J Infect Dis. 2021 Jun;107:212-214
pubmed: 33930544
BMJ. 2021 Mar 10;372:n436
pubmed: 33692022
Kidney Blood Press Res. 2021;46(5):620-628
pubmed: 34315161
J Clin Virol. 2020 Jun;127:104378
pubmed: 32353762
J Diabetes Metab Disord. 2021 Jan 07;20(1):59-69
pubmed: 33432296
Caspian J Intern Med. 2020 Fall;11(Suppl 1):544-550
pubmed: 33425273
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Sci Rep. 2020 Nov 24;10(1):20452
pubmed: 33235220
Hematology. 2020 Dec;25(1):383-388
pubmed: 33124971
Front Public Health. 2021 Jan 15;8:582932
pubmed: 33520910
Chaos. 2021 Mar;31(3):031105
pubmed: 33810707
J Diabetes Metab Disord. 2021 Nov 08;20(2):1545-1555
pubmed: 34778117
Intern Emerg Med. 2020 Nov;15(8):1415-1424
pubmed: 32772283
Infect Control Hosp Epidemiol. 2020 Jun;41(6):754-755
pubmed: 32192541
J Infect. 2021 Jun;82(6):e14-e15
pubmed: 33826927